Article thumbnail

Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells.

By H. Chung, Y. S. Kang, C. S. Hwang, I. K. Moon, C. H. Yim, K. H. Choi, K. O. Han, H. C. Jang, H. K. Yoon and I. K. Han


Information on precise effects of deflazacort on bone cell function, especially osteoclasts, is quite limited. Therefore, the present study was undertaken to test effects of deflazacort on osteoclast-like cell formation in mouse bone marrow cultures and on the regulation of osteoprotegerin (OPG) and its ligand (RANKL) mRNA expressions by RT-PCR in the ST2 marrow stromal cells. TRAP-positive mononuclear cells increased after the treatment of deflazacort at 10(-9) to 10(-7) M alone for 6 days in a dose-dependent manner. Number of TRAP-positive multi-nucleated cells (MNCs) increased significantly with combined treatment of deflazacort at 10(-7) M and 1,25-(OH)2D3 at 10(-9) M compared to that of cultures treated with 1,25-(OH)2D3 alone (p<0.05). Exposure to deflazacort at 10(-7) M in the presence of 1,25-(OH)2D3 at 10(-9) M in the last 3-day culture had greater stimulatory effect on osteoclast-like cell formation than that of the first 3-day culture did. Deflazacort at 10(-10) -10(-6) M downregulated OPG and upregulated RANKL in mRNA levels in a dose-dependent manner. These observations suggest that deflazacort stimulate osteoclast precursor in the absence of 1,25-(OH)2D3 and enhance differentiation of osteoclasts in the presence of 1,25-(OH)2D3. These effects are, in part, thought to be mediated by the regulation of the expression of OPG and RANKL mRNA in marrow stromal cells

Topics: Research Article
Publisher: Korean Academy of Medical Sciences
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1991). A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum
  2. (1998). Bone histomorphometry in glucocorticoid-induced osteoporosis.
  3. (1996). Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica-a double blind prospective comparison between prednisolone and deflazacort. Ann Rheum Dis
  4. (1973). Corticosteroid osteoporosis. Clinics Endocrinol Metab
  5. (1993). Cytokines and estrogen in bone: anti-osteoporotic effects. Science
  6. (1995). cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.
  7. (1998). Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology
  8. (1997). Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res
  9. (1994). Dexamethasone stimulates osteoclast-like cell formation by inhibiting granulocyte-macrophage colony stimulating factor production in mouse bone marrow cultures. Endocrinology
  10. (1984). Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int
  11. (1987). Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int
  12. (1992). Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int
  13. (1983). Glucocorticoid-induced osteoporosis.
  14. (1982). Glucocorticoids and intestinal absorption of calcium and phosphate in man. In:
  15. Mechanisms of glucocorticoid action in bone cells.
  16. (1988). Osteoblastic cells are involved in osteoclast formation. Endocrinology
  17. (1988). Osteoclast-like cell formation and its regulation by osteotrophic hormones in mouse bone marrow cultures. Endocrinology
  18. (2000). Osteoprotegerin and osteoprotegerin ligand mediated the local regulation of bone resorption. Endocrinologist
  19. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell
  20. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell
  21. (1999). Stimulation of osteoprotegerin ligand and inhibiton of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoidinduced osteoporosis. Endocrinology
  22. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the . .Deflazacort Effects on Osteoclast Formation 773 paracrine regulation of bone resorption.